This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Anne Messer, PhD
Principal Investigator at Neural Stem Cell Institute


Anne Messer holds a PhD in Molecular Biology from the Univ. Oregon Institute of Molecular Biology, and did neurogenetics postdoctoral work as a Helen Hay Whitney postdoctoral fellow and then instructor at Harvard Medical School. During her tenure as an independent neurogenetics research scientist at the Wadsworth Center of the NY State Department of Health (directing the Molecular Genetics Program, and the Laboratory of Human Genetics), and professor of Biomedical Sciences, Univ. at Albany (founding chair of the neuroscience track), she has published over 100 papers on genetics, mechanisms, and therapeutics for neurodevelopmental and neurodegenerative diseases, including papers in Nature, Nature Genetics, Proceedings of the National Academy of Sciences, Molecular Therapy, and major neuroscience journals. She has been funded by multiple NIH grants and several disease foundations, while reviewing grants for over 30 NIH study section meetings, and 20 national and international funding agencies. In the late 1990s, she pioneered the use of engineered antibody fragments (nanobodies / intrabodies) to counteract the cellular effects of misfolding proteins in stressed and aging cells. Since then, she has amassed a body of publications applying this technology to Huntington’s and Parkinson’s disease, ranging from antibody engineering and nanobody selection to in vivo delivery by novel gene therapies. Multiplexed and fusion intrabodies show great promise in preclinical studies. Having joined the Neural Stem Cell Institute, headed by her long-term colleagues, Drs. Sally Temple and Jeff Stern, human stem cells and organoids allow powerful test platforms for further development.

Agenda Sessions

  • Co-Chairs’ Remarks